Literature DB >> 9036918

Mutations in the COL3A1 gene result in the Ehlers-Danlos syndrome type IV and alterations in the size and distribution of the major collagen fibrils of the dermis.

L T Smith1, U Schwarze, J Goldstein, P H Byers.   

Abstract

Ehlers-Danlos syndrome type IV (EDS type IV) results from heterozygosity for mutations in the COL3A1 gene that encodes the chains of type III procollagen. By using light, transmission, and scanning electron microscopy, we examined skin biopsies from 22 individuals with EDS type IV in whom the COL3A1 mutations had been identified. The most striking changes in EDS type IV were correlated with point mutations that substituted a residue for a glycine near the carboxyl-terminal end of the triple-helical domain of pro alpha1(III). In three cases with the mutation G1012R, G1018V, or G1021E, cells in the dermis had extremely dilated rough endoplasmic reticulum (RER), the dermis was thin, and there was a reduced proportion of collagen although the proportion of elastic fibers appeared increased. In these tissues, collagen fibrils were small (65-80 nm) compared to normal (95-110 nm). Fibrils 80-90 nm in diameter and moderately dilated RER were found with mutations G769R, G373R, and G061E and with exon-skipping mutations of exons 34 and 45. With mutations G034R and G016C and exon-skipping mutations that deleted the sequences of exons 7, 8, 14, 18, 24, and 27, fibrils were more variable in size (85-120 nm). The composite collagen fibrils characteristic of EDS types I and II were not found in EDS type IV. These findings indicate that mutations in the COL3A1 gene have effects on secretion, fibrillogenesis, and skin architecture that reflect the position and nature of the mutation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9036918     DOI: 10.1111/1523-1747.ep12286441

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  20 in total

1.  Location of glycine mutations within a bacterial collagen protein affects degree of disruption of triple-helix folding and conformation.

Authors:  Haiming Cheng; Shayan Rashid; Zhuoxin Yu; Ayumi Yoshizumi; Eileen Hwang; Barbara Brodsky
Journal:  J Biol Chem       Date:  2010-11-11       Impact factor: 5.157

2.  Molecular diagnosis in vascular Ehlers-Danlos syndrome predicts pattern of arterial involvement and outcomes.

Authors:  Sherene Shalhub; James H Black; Alana C Cecchi; Zhi Xu; Ben F Griswold; Hazim J Safi; Dianna M Milewicz; Nazli B McDonnell
Journal:  J Vasc Surg       Date:  2014-03-18       Impact factor: 4.268

Review 3.  The final stage of gene expression: chaperones and the regulation of protein fate.

Authors:  J Ashkenas; P H Byers
Journal:  Am J Hum Genet       Date:  1997-08       Impact factor: 11.025

4.  A multi-institutional experience in the aortic and arterial pathology in individuals with genetically confirmed vascular Ehlers-Danlos syndrome.

Authors:  Sherene Shalhub; Peter H Byers; Kelli L Hicks; Kristofer Charlton-Ouw; Devin Zarkowsky; Dawn M Coleman; Frank M Davis; Ellen S Regalado; Giovanni De Caridi; K Nicole Weaver; Erin M Miller; Marc L Schermerhorn; Katie Shean; Gustavo Oderich; Mauricio Ribeiro; Cole Nishikawa; Christian-Alexander Behrendt; E Sebastian Debus; Yskert von Kodolitsch; Richard J Powell; Melanie Pepin; Dianna M Milewicz; Peter F Lawrence; Karen Woo
Journal:  J Vasc Surg       Date:  2019-05-21       Impact factor: 4.268

Review 5.  The Ehlers-Danlos syndromes.

Authors:  Fransiska Malfait; Marco Castori; Clair A Francomano; Cecilia Giunta; Tomoki Kosho; Peter H Byers
Journal:  Nat Rev Dis Primers       Date:  2020-07-30       Impact factor: 52.329

6.  Doxycycline ameliorates the susceptibility to aortic lesions in a mouse model for the vascular type of Ehlers-Danlos syndrome.

Authors:  Wilfried Briest; Timothy K Cooper; Hyun-Jin Tae; Melissa Krawczyk; Nazli B McDonnell; Mark I Talan
Journal:  J Pharmacol Exp Ther       Date:  2011-03-01       Impact factor: 4.030

Review 7.  Type III collagen (COL3A1): Gene and protein structure, tissue distribution, and associated diseases.

Authors:  Helena Kuivaniemi; Gerard Tromp
Journal:  Gene       Date:  2019-05-07       Impact factor: 3.688

8.  Targetable cellular signaling events mediate vascular pathology in vascular Ehlers-Danlos syndrome.

Authors:  Caitlin J Bowen; Juan Francisco Calderón Giadrosic; Zachary Burger; Graham Rykiel; Elaine C Davis; Mark R Helmers; Kelly Benke; Elena Gallo MacFarlane; Harry C Dietz
Journal:  J Clin Invest       Date:  2020-02-03       Impact factor: 14.808

9.  Ultrastructural scoring of skin biopsies for diagnosis of vascular Ehlers-Danlos syndrome.

Authors:  Kim-Thanh Ong; Henri Plauchu; Simone Peyrol; Elisabeth Roux; Elisabeth Errazuriz; Philippe Khau Van Kien; Brigitte Arbeille; Alain Gaulier; Gabriela Georgescou; Patrick Collignon; Dominique P Germain; Marie-Noëlle Gaveau; Jérôme Perdu; Stéphane Laurent; Patrick Bruneval; Pierre Boutouyrie
Journal:  Virchows Arch       Date:  2012-05-02       Impact factor: 4.064

10.  Vascular Ehlers-Danlos syndrome: exploring the role of inflammation in arterial disease.

Authors:  Dianna M Milewicz; Amy J Reid; Alana C Cecchi
Journal:  Circ Cardiovasc Genet       Date:  2014-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.